TrialNet: University of Florida Clinical Center and Network

TrialNet：佛罗里达大学临床中心和网络

• 批准号: 8776517
• 负责人: DESMOND Arthur SCHATZ
• 金额: $ 68.75万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2019-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8776517
• 关键词: Adolescent; Adult; American; Cell Survival; Cell physiology; Cells; Child; Clinical; Clinical Trials; Collaborations; Development; Diabetes Mellitus; Diagnosis; Disease; Environment; Financial cost; Florida; Funding; Future; Goals; Individual; Institution; Institutional Review Boards; Insulin-Dependent Diabetes Mellitus; Intervention; Monitor; National Institute of Diabetes and Digestive and Kidney Diseases; Performance; Persons; Prevention; Relative (related person); Research; Research Infrastructure; Research Personnel; Residual state; Risk; Societies; Testing; United States National Institutes of Health; Universities; clinical risk; cost; design; disorder prevention; disorder risk; effective intervention; follow-up; innovation; member; non-diabetic; novel strategies; outreach; prevent; public health relevance; screening

DESCRIPTION (provided by applicant): The University of Florida, a founding member of the DPT-1 and the internationally constituted diabetes trial network (Type 1 Diabetes TrialNet), has made significant and important contributions to TrialNet and type 1 diabetes (T1D), where it participates as one of the top performing Clinical Centers. The primary goal of TrialNet is to prevent and/or delay the development of T1D in persons at risk for the disease by testing interventions targeted at decreasing ¿-cell destruction and/or enhancing ¿-cell survival. The University of Florida seeks to continue serving as a Clinical Center as part of the TrialNet network. The NIH TrialNet RFA intends to continue providing support for highly productive centers by funding the necessary infrastructure that would enable screening large numbers of T1D relatives so as to identify those at risk of clinical disease. Continuing TrialNet membership would enable our established and highly successful University of Florida Clinical Center and its strong Affiliate network to continue supporting subject recruitment into studies, enhancing trial performance, subject retention, and follow-up. Indeed, our Center is poised to continue the quest for the future prevention and reversal of T1D through its outstanding environment and innovative investigators with proven approaches, each dedicated to identifying a means to prevent/cure the disease as well as to enhance recruitment and retention for T1D clinical trials. In responding to this RFA, this application describes: 1) Unique strengths and contributions of the institution to TrialNet and the T1D field; 2) Ongoing and novel strategies to identify and maintain an active Affiliate network; 3) Recruitment, outreach, and collaboration plans; 4) Strategies to enhancing cost efficiency; 5) Performance monitoring; 6) Consideration of federated IRB; 7) Development of future T1D clinical researchers; and 8) Potential opportunities and challenges for the prevention of T1D currently and over the next 5 years.

描述（由适用提供）：佛罗里达大学是DPT-1的创始成员以及国际组织的糖尿病试验网络（1型糖尿病试验网络），对试验网和1型糖尿病（T1D）做出了重要而重要的贡献，它是表现出色的临床中心之一。试验网的主要目的是通过测试旨在减少细胞破坏和/或增强细胞生存的靶标干预措施来预防和/或延迟患有疾病风险的T1D的发展。佛罗里达大学试图继续作为试验网络的一部分担任临床中心。 NIH试验网RFA打算通过资助必要的基础设施来继续为高生产力提供支持，以筛选大量T1D亲戚，从而确定有临床疾病风险的基础设施。持续的试用网络会员资格将使我们建立的佛罗里达大学临床中心及其强大的会员网络能够继续支持学科招募研究，增强试验绩效，主题保留和随访。的确，我们的中心被毒死，以继续寻求未来的预防和T1D通过其杰出的环境和创新的研究人员的逆转，并采用了良好的方法，每种都致力于确定一种预防/治愈该疾病的方法，并增强T1D临床试验的招募和保留率。在响应此RFA时，该申请描述了：1）机构对试验网和T1D领域的独特优势和贡献； 2）正在进行的策略和新颖的策略，以识别和维护主动的会员网络； 3）招募，外展和协作计划； 4）提高成本效率的策略； 5）性能监控； 6）考虑联邦IRB； 7）发展未来的T1D临床研究人员； 8）目前和未来5年预防T1D的潜在机会和挑战。